For example, a chimeric antigen receptor (CAR) T cell could be utilized in this context either by potentially using a 4th generation TRUCK CAR‐T cell model, transferring the expressed miRNAs directly to the tumour site54 or by loading PD‐L1 suppressing miRNAs on CAR‐T produced exosomes for increased homing and lower patient toxicity.55 The gene discussed is CD274; the disease is neoplasm.